Pictet Asset Management SA grew its position in shares of uniQure (NASDAQ:QURE – Get Rating) by 39.2% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 164,535 shares of the biotechnology company’s stock after purchasing an additional 46,332 shares during the period. Pictet Asset Management SA’s holdings in uniQure were worth $3,067,000 as of its most recent SEC filing.
A number of other hedge funds also recently made changes to their positions in QURE. Nisa Investment Advisors LLC raised its stake in shares of uniQure by 60.0% during the first quarter. Nisa Investment Advisors LLC now owns 4,000 shares of the biotechnology company’s stock valued at $72,000 after purchasing an additional 1,500 shares during the period. Envestnet Asset Management Inc. increased its stake in shares of uniQure by 16.4% in the first quarter. Envestnet Asset Management Inc. now owns 60,334 shares of the biotechnology company’s stock worth $1,090,000 after buying an additional 8,479 shares during the last quarter. Banque Pictet & Cie SA increased its stake in shares of uniQure by 4.0% in the first quarter. Banque Pictet & Cie SA now owns 79,041 shares of the biotechnology company’s stock worth $1,428,000 after buying an additional 3,059 shares during the last quarter. Victory Capital Management Inc. bought a new stake in shares of uniQure in the first quarter worth $224,000. Finally, IndexIQ Advisors LLC increased its stake in shares of uniQure by 1,824.0% in the first quarter. IndexIQ Advisors LLC now owns 23,146 shares of the biotechnology company’s stock worth $418,000 after buying an additional 21,943 shares during the last quarter. Hedge funds and other institutional investors own 86.46% of the company’s stock.
uniQure Stock Performance
QURE stock opened at $22.18 on Monday. The company has a market capitalization of $1.04 billion, a P/E ratio of -8.25 and a beta of 0.96. The company has a 50-day simple moving average of $19.43 and a 200 day simple moving average of $18.92. uniQure has a fifty-two week low of $12.52 and a fifty-two week high of $30.41. The company has a quick ratio of 7.20, a current ratio of 7.26 and a debt-to-equity ratio of 0.24.
Insider Buying and Selling
Analysts Set New Price Targets
A number of brokerages recently issued reports on QURE. Chardan Capital dropped their price target on shares of uniQure from $65.00 to $60.00 and set a “buy” rating for the company in a research note on Tuesday, August 9th. StockNews.com initiated coverage on shares of uniQure in a report on Wednesday, October 12th. They issued a “sell” rating for the company. TheStreet downgraded shares of uniQure from a “c-” rating to a “d” rating in a report on Tuesday, August 9th. Wells Fargo & Company decreased their price objective on shares of uniQure from $34.00 to $24.00 and set an “equal weight” rating for the company in a report on Tuesday, August 9th. Finally, William Blair reaffirmed an “outperform” rating on shares of uniQure in a report on Wednesday, November 2nd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $45.43.
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis.
- Get a free copy of the StockNews.com research report on uniQure (QURE)
- Is GameStop Stock Setting Up for Another Short Squeeze?
- Here’s Why SoFi Technologies Stock is Cheap at These Levels
- Warren Buffet Bought Taiwan Semiconductor Stock, Should You?
- MarketBeat: Week in Review 11/14 – 11/18
- Target’s Double Bottom Might Have Just Been Confirmed
Receive News & Ratings for uniQure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure and related companies with MarketBeat.com's FREE daily email newsletter.